Navigation Links
Icahn Asks Amylin to Allow Discussions With Eastbourne
Date:4/23/2009

NEW YORK, April 23 /PRNewswire/ -- Carl Icahn announced today that he had sent the following letter to James Wilson, Lead Independent Director of Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN).

                                        April 23, 2009

    Mr. James Wilson
    Lead Independent Director
    Amylin Pharmaceuticals, Inc.
    9360 Towne Centre Drive
    San Diego, CA  92121

    Dear Jim:

    If you are really serious about settling what you consider a debilitating
    proxy contest, I believe it is mandatory for you to take the necessary
    action to allow Eastbourne and myself to talk without the threat of your
    poison pill and Section 203 preventing these discussions.  It is almost
    absurd that I and Eastbourne, separately, have had to ask you a number of
    times during last week and the week before to get permission to have these
    talks.  As I have said, even in a dictatorship parties that disagree with
    the ruling regime are allowed to talk to each other.  But not at Amylin.

    I sincerely believe that as a result of these discussions and subsequent
    discussions among the three of us, there will be enough common ground to
    resolve the matter.  What exactly are you afraid of?  The alternative is
    for the Company and its stockholders to continue to be distracted because
    of the inexplicable intransigence of the current Board which continues to
    evidence itself in so many ways, e.g. the poison pill, the poison puts,
    and the failure to heed the views of your co-founder, Howard E. Greene,
    Jr., regarding Joseph Cook's board seat.

    I look forward to your prompt response.

                                        Sincerely,

                                        Carl Icahn

SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER D
'/>"/>

SOURCE Carl Icahn
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Icahn Responds to Cornelius
2. Icahn Confirms Intention to Nominate Three Directors at Biogen
3. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
4. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
5. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
6. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
7. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
8. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
9. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
10. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
(Date:3/4/2015)... , March 4, 2015 AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... and breakthrough pain, today announced that it will ... after market close on Monday, March 9th, 2015. ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ...
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
(Date:3/3/2015)... Experts and industry insiders from around the world ... REBELation exploring innovation, inspiration and world-changing ideas in Lexington, ... year, Alltech’s annual international conference traditionally draws more than ... join the REBELation at an extra discount registration closes ... which point the standard early registration rate will apply. ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... OncoGenex Pharmaceuticals, Inc (NASDAQ: OGXI ) will ... at the RBC Capital Markets 2008 Healthcare Conference on ... Westin Times Square Hotel in New York. During the ... Cormack, will provide a brief overview of the company,s ...
... ConjuChem,s, R&D Efforts -, ... BAGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies Inc. ... Novozymes A/S (LSE:NVZ) announced today that the Companies have ... which Novozymes Biopharma will exclusively supply its recombinant human ...
... BioSciences, Inc., announced,today that it has expanded the ... Stent System with NanoThin Polyzene(R)-F -- a stent,system ... clinical studies. It is CE,Marked and available for ... with aggressive world-wide expansion ongoing. Concurrently,CeloNova notes that ...
Cached Biology Technology:ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 2ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 3CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 2CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 3
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... news release is available in Spanish . ... collaboration of university students analysed the effect of weekend alcohol consumption ... DNA. Until now, the damage to the packaging of nuclear material ... perhaps because most of the studies are done at later stages ...
... in the United States increased from 14.5% of the population ... believed that one contributing factor to expanding waistlines is the ... to control energy intake may be affected by the speed ... impair the relationship between the sensory signals and processes that ...
... The chitosan molecule can promote nerve cell adherence and ... enhance the adherence and influx of Schwann cells, thus ... by a nerve conduit may not be sufficient to ... Institute of Stomatology, Chinese PLA General Hospital in China ...
Cached Biology News:Alcohol leaves its mark on youngsters' DNA 2Alcohol leaves its mark on youngsters' DNA 3Slower-paced meal reduces hunger but affects calorie consumption differently 2Slower-paced meal reduces hunger but affects calorie consumption differently 3
Candida (IgA) -Ab EIA Sample Size: 5 l...
... Arabidopsis thaliana is the first higher plant ... serves as the primary model organism for ... content on this microarray is derived from ... for Genomic Research (TIGR) and from the ...
... with its manganese-containing reaction buffer, converts long ... short (1825 bp) interfering RNAs (siRNA) suitable ... units (1 l) of ShortCut RNase III ... dsRNA into siRNA suitable for RNA interference ...
EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
Biology Products: